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T
he identiﬁcation and study of autoimmune dis-
eases has taught us that recognition of self-
antigens can have devastating consequences. Yet
there is a paradox to autoreactivity: when cor-
rectly balanced, it is at the heart of robust self-tolerance.
This concept gives rise to several questions. Can this
balance be manipulated? And if so, by what means and
through which mechanisms? What are the rules that
govern this opportunity to restore homeostasis?
Studies in a variety of animal models, which act as
replicas of the major chronic inﬂammatory diseases that
affect humans, have offered many answers to these ques-
tions. One of the clearer outcomes is that delivery of
autoantigens, administered at different disease stages via a
variety of routes, can provide robust, sustained health and
protection from inﬂammatory autoimmune disease. The
most appealing element to this approach, termed antigen-
speciﬁc immunotherapy (ASI), has been that it not only
provides an effective means of controlling the autoimmune
response via induction or restoration of -cell–speciﬁc
tolerance, but that it may achieve these goals without
major concerns over safety and certainly without the
specter of immune suppression. Yet signiﬁcant questions
remain. Are we doing enough to realize the potential of
this sacred cow? How do we move from concept to
reality?
In this article, we provide an update on the mechanisms
through which ASI is currently thought to operate. We
discuss why, despite this body of knowledge, alternative,
non-ASI approaches have emerged as the current vogue.
We argue that more should be done to counter this trend
and realize the potential of ASI, including strategies that
combine its strengths with those of other complementary
ways forward.
Mechanisms of therapeutic effect including evidence
from human trials. Predicting the outcome of immuniza-
tion with islet antigens is complex. The resulting immune
response depends not only on the dose, frequency, and
route of administration but also on the precise context, in
which the use of suitable adjuvants and inﬂammation can
profoundly inﬂuence the resulting immune response or
lack thereof. In addition, one should expect interindividual
variations in the autoreactive repertoire of T-cells: some
islet-reactive T-cells might already be activated at the time
of immunization and their avidities can be expected to
vary depending on central (thymic) and peripheral tuning
events, which in turn will inﬂuence the character (magni-
tude and cytokine production) of the resulting antigen-
speciﬁc response. The underlying mechanisms are more
apparent in murine studies, but evidence is also beginning
to emerge from human studies in vivo, both in autoimmu-
nity and comparable inﬂammatory settings. The two main
outcomes involve the induction or augmentation of bene-
ﬁcial (regulatory) immune responses (1–3) and the elimi-
nation (deletion) of deleterious islet–speciﬁc effector
responses (4–6), both of which are context-dependent and
will be discussed below (Table 1). It is self-evident that
both outcomes could be beneﬁcial in type 1 diabetes (Fig.
1) where there may be both a regulatory T-cell (Treg)
defect and effector cells that are relatively resistant to
regulation (7).
Studies in mice have clearly documented the enhance-
ment of Tregs and the skewing of cytokine responses
(immune deviation) after mucosal (oral, nasal) or periph-
eral (peptide with and without adjuvant, DNA vaccination)
insulin, proinsulin, or other autoantigenic peptide admin-
istration (8,9). In these experiments, repeated administra-
tion of -cell autoantigens, most notably insulin or its
peptides, led to increased interleukin (IL)-4, IL-10, and
transforming growth factor (TGF)- production by insulin-
speciﬁc polyclonal T-cell populations isolated from the
spleen, pancreatic lymph nodes, and, in some cases, the
islets. Unfortunately the numbers of autoreactive T-cells in
the blood are low and, therefore, little information is
available about their frequency and function in peripheral
blood, which would be very helpful to guide human
biomarker efforts. The antigen-induced or enhanced cell
populations can actively suppress effector immune re-
sponses as evidenced by adoptive transfer studies. Unless
they are enabled by certain chemokines or chemokine
receptors or integrins to home to solid organs, the antigen-
induced modulating cells are usually found in lymph nodes
and spleens following transfer into pre-diabetic recipient
mice. Thus, antigenic immunization can endow islet-reac-
tive T-cells with the ability to regulate and suppress
deleterious effector responses, which entitles them to be
called adaptive regulatory T-cells (aTregs). In some cases,
the transcription factor forkhead box P3 (FoxP3), a good
marker for naturally occurring Tregs (nTregs), shows
increased expression. FoxP3 is of value as a bona ﬁde Treg
marker in the mouse, but its utility in humans is much
more limited because it is also expressed on recently
activated effector T-cells. Thus, successful ASIs that pre-
vent type 1 diabetes in animal models are associated with
the induction of cytokines, which can be considered as
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are produced by CD4 T-cells that can function as aTregs.
In this context, the difference between immune deviation
and Treg induction is mainly a semantic argument. The
control of effector responses of various speciﬁcities (by-
stander suppression) likely occurs through modulation of
antigen-presenting cells (APCs) resulting in a lack of
anti-islet effector T-cell expansion, but not their deletion.
New alternative models have also been described recently
in which APCs are perhaps incapacitated from their role of
antigen presentation to autoreactive effector T-cells
through a direct APC-lytic process mediated by Tregs both
in vitro in man and in vivo in murine studies (10,11).
Similarly, immune deviation indicative of Treg genera-
tion has been documented in humans (for example, the
induction of a proinsulin peptide–speciﬁc IL-10 response
after low dose intradermal administration of the peptide in
type 1 diabetic patients) (12), reminiscent of observations
in studies of peptide immunotherapy in clinical allergy
(13,14). Other examples are the signiﬁcant increases in
GAD-speciﬁc -interferon, IL-5,-13,-10,-17,-6, tumor necro-
sis factor-, FoxP3, and TGF- mRNA responses as well as
autoantibody induction (15) following subcutaneous ad-
ministration of 20 g of recombinant human GAD65
adsorbed onto alum (in a classic prime-boost regimen, n 
35/group). In other clinical trials where the limited effects
of ASI have been documented, for example after daily
dosing of oral insulin (16) or after a proinsulin-expressing
DNA vaccine (17), no such clear effects as of yet have been
documented and will have to await future biomarker
studies.
The strong clinical advantage of modulating the -cell–
speciﬁc immune response and redirecting its aggressive
nature to a more regulatory function is that the resulting
aTregs can suppress heterologous islet–speciﬁc effector
responses, and they can do so in a site-speciﬁc manner
because they are predicted to become active only at sites
where islet antigens are being presented. Thus, in a sense,
ASI offers a site-speciﬁc immune modulatory drug. The
clinical disadvantage is that antigen-speciﬁc therapies may
have less potency than directly immunosuppressive strat-
egies, as evidenced by the fact that they tend only to work
prior to onset of diabetes in preclinical models. Transla-
tion to man may therefore require deployment at the early
stages of pre-diabetes or enhancement with other comple-
mentary strategies (see below). Thus, optimization of
dosing and delivery regimens for ASI in parallel with the
development of suitable adjunct therapies needs to be
considered as a major priority area (see the detailed
discussion below).
The current clinical trial landscape in type 1 diabe-
tes: a question of balance. Given the many potential
advantages of ASI over non-ASI discussed heretofore
(safety, prospect of tolerance, site-speciﬁc regulation), it
might be expected that clinical strategies based around
antigens would be pursued vigorously and in many quar-
ters. Paradoxically, however, this is far from being the
case (Fig. 2). A snapshot view of major studies (as
opposed to small-scale pilots) that have been completed
and published, are currently in progress, or are at an
advanced stage of planning indicates that at the stages of
disease that are often referred to as primary and second-
ary prevention, ASI is indeed the dominant modality under
investigation. However, there is much more clinical trial
TABLE 1
Mechanisms of action of antigen-speciﬁc immunotherapy and predicted nature of response
Mechanism Predicted outcomes Tolerance induction Durability
Immune regulation induced
against -cell antigen
(typically associated with
aTregs, IL-10, TGF-
induction)
Responses should be detectable
(e.g., by cytokine production
or functional read-out)
Operational tolerance should
be achieved
Responses durable in the
range of months up to
1 year
Should offer beneﬁt of linked
suppression of response to
other -cell antigens
Immune deviation associated
with change of dominant
cellular phenotype (e.g.,
from TH1t oT H2)
Responses should be detectable
(e.g., by cytokine production
or functional read-out)
Operational tolerance should
be achieved
Responses durable in the
range of months
May offer beneﬁt of linked
suppression
Immune deletion of -cell
antigen-speciﬁc T-cells
Difﬁcult to detect deletion Operational tolerance not
guaranteed
Transient (weeks/months)
No beneﬁt of linked
suppression
β cells  
#$"
TH1
CTL 
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and inflammation 
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FIG. 1. Beneﬁcial effects of antigen-speciﬁc immunotherapy (ASI) on
the pathological immune responses that result in type 1 diabetes. -cell
damage is a result of the combined actions of proinﬂammatory helper
T cells (TH1) and cytotoxic T lymphocytes (CTL), which are primed
against islet autoantigens such as GAD65 (GAD) and preproinsulin
(INS) by inﬂammatory dendritic cells (DCs). ASI has two predominant
beneﬁcial effects, namely deletion of T-cells and induction of regula-
tion, either via priming of regulatory T-cells (Tregs) or immune
deviation. The major beneﬁt of Treg induction is linked suppression,
the process by which Tregs induced to regulate in response to one
autoantigen (e.g., GAD) can also regulate responses to other autoan-
tigens (e.g., INS) presented by the same DC.
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very close to diagnosis), and many more of the agents
under evaluation are non-ASIs, especially when one con-
siders the trials that are currently active. In general the ASI
studies are low-risk and dominated by a single antigen,
insulin. There is a sense that the desire to conduct studies
in the prevention arena has led to trials of the very safest
of drugs (e.g., injectable insulin), but these trials have not
necessarily been fully optimized for efﬁcacy.
There are numerous explanations for this evident bias
toward evaluation of novel non-ASI reagents at the inter-
vention stage (Table 2).
Perhaps most worrying are 1) the limited involvement of
the biotechnology and pharmaceutical industries in devel-
oping ASI and 2) the fact that assessing ASI at the
intervention stage and expecting favorable metabolic out-
comes in order that a full program of development can be
progressed is a very hostile environment for these
“weaker” therapies. The upshot is that this important
treatment modality is not being evaluated in sufﬁcient
depth at the safest stage of disease (because the patients
already have diabetes) when the acquisition of subjects is
the least expensive (because screening is not required).
Given that the collective ability to conduct rationally
designed biomarker analyses has improved markedly in
the last 10 years or so (18), it would make sense for ASI to
be evaluated in the intervention setting more on the basis
of its effect on biomarkers than on metabolic outcomes.
Risk analysis for antigen-speciﬁc immunotherapy.
There are three major areas of concern for the use of ASI
in type 1 diabetes: acceleration of disease, leading to more
rapid -cell loss; induction of life-threatening hypersensi-
tivity; and induction of “off-target” autoimmunity. The ﬁrst
two of these will need to be discussed with prospective
subjects being enrolled into any prevention or intervention
study that uses an antigen-based approach, whereas the
third area of concern is antigen-dependent and will there-
fore depend upon the nature of the trial.
The picture in relation to ASI and disease acceleration in
nonclinical studies is generally reassuring. For example,
an extensive analysis of the literature in relation to the
nonobese diabetic (NOD) model of spontaneous autoim-
mune diabetes (in which, for example, approximately 100
published studies since 1996 have involved injection or
ingestion of whole or peptide autoantigens, either as
simple solutions or in conjunction with powerful adju-
vants) has revealed that it is extremely unusual to accel-
erate disease; in most cases the maneuvers are protective
or have no effect. In one reported study, disease was
accelerated. In that case, two peptides of the -cell au-
0 
Years 
100 
1° prevention  2° prevention  Intervention 
•DPT-1 oral insulin 
•DPT-1 parenteral 
insulin 
•DIPP 
•INIT intranasal insulin 
•Oral insulin TrialNet 
•[GAD-alum prevention 
TrialNet & Diamyd] 
•Pre-Point 
(oral insulin) 
•Insulin APL 
•Insulin B chain +IFA 
•Proinsulin peptide 
•Proinsulin DNA 
•Insulin-PBMC 
•DiaPep277 
•GAD-alum  TrialNet/
Diamyd  
•Cyclosporine 
•Anti-CD3 
•Anti-CD20 
•ATG 
•Autologous HSCT 
•MMF/DZB 
•CTLA-4Ig 
•Anti-IL-1β (x3) 
•Anti-TNF-α
•IL-2 & Rapa 
•ATG & GCSF 
•α1-AT 
•Gleevec 
•IL12/23 
•Anti-CD2 
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FIG. 2. Schematic representation of the balance of clinical trial activity in type 1 diabetes. Data are modeled onto a graphical representation of
diabetes progression (adapted from reference [38]; reprinted with permission from Atkinson). Data are separated in two dimensions. First,
according to stage of disease (primary prevention in the genetically at-risk before autoimmunity is apparent; secondary prevention when
autoimmunity is present but no disease; and tertiary prevention or intervention when diabetes has been diagnosed but there is the opportunity
to preserve C-peptide secretion); second, according to whether the therapy is antigen-speciﬁc (in black) or nonantigen-speciﬁc (in red).
Underlined therapies are currently actively recruiting. The pie charts indicate the relative proportions of antigen-speciﬁc (black) and
nonantigen-speciﬁc immunotherapy (red) in use at the different disease stages. DIPP, Diabetes Prediction and Prevention (39); APL, altered
peptide ligand (40); ATG, anti-thymocyte globulin; CTLA-4Ig, cytotoxic T lymphocyte antigen-4 immunoglobulin; GCSF, granulocyte colony
stimulating factor; HSCT, hematopoietic stem cell transplant; IFA, incomplete Freund’s adjuvant; IL-1, interleukin-1; MMF/DZB, mycopheno-
late mofetil and daclizumab (41); 1-AT, -1 antitrypsin; PBMC, peripheral blood mononuclear cell; TNF-, tumor necrosis factor-.
M. PEAKMAN AND M. VON HERRATH
diabetes.diabetesjournals.org DIABETES, VOL. 59, SEPTEMBER 2010 2089toantigen GAD65 were administered intrathymically and
caused a mild acceleration of diabetes onset in NOD mice
(19). The authors pointed out that immunization with
whole GAD65 does not induce CD4 T-cells reactive with
either peptide used, implying that these are cryptic
epitopes not naturally processed and presented by NOD
mouse APCs. The route of administration may also be
important in this outcome—our own studies injecting a
single dose of one of these cryptic GAD65 epitopes intra-
peritoneally gave a strong protective effect (20). The use of
naturally processed and presented epitopes or whole
antigens may be an important safeguard against the danger
of priming additional T-cells with cryptic peptides. Other
examples of disease exacerbation by autoantigen admin-
istration in models of autoimmune demyelination (21) and
autoimmune diabetes (22) have also been reported, but
these appear to be rare occurrences. In clinical studies, the
experience is obviously much less extensive. It is notable
that in the study of oral insulin administration to ﬁrst-
degree relatives with insulin autoantibodies, the subgroup
analysis of those who did not have conﬁrmed insulin
autoantibodies 80 nU/ml suggested a trend toward a
detrimental effect of the treatment (16), reminding us that
we may need to develop carefully argued selection algo-
rithms for trial entry. The examples of disease exacerba-
tion in multiple sclerosis (MS) using altered peptide
ligands of the autoantigen myelin basic protein is yet
another strong argument for using native peptide se-
quences or whole antigens (23,24). Apart from these
examples, there has been no evidence of disease exacer-
bation from ASI trials in rheumatoid arthritis (25,26) or
more recent studies of MS patients using native sequence
peptides (27).
A second safety consideration raised by published non-
clinical studies is the risk that antigen injection can result
in hypersensitivity, systemic allergy, and anaphylaxis. The
most relevant report here was of fatal anaphylaxis in NOD
mice after repeated injections of an immunodominant
peptide of insulin (residues B9–23). However, relatively
large quantities (total 1 mg) and repeated (seven times)
dosing of peptide were used in these studies (28). These
responses may have been idiosyncratic to this strain and
were alleviated by the alteration of the peptide’s isoelec-
tric point (29). Such responses have not been seen to date
in the setting of autoimmune disease in man (apart from
the altered peptide ligand studies in MS discussed above,
in which hypersensitivity responses were also observed).
It may be that the induction of T helper 2 (TH2)-like
responses requires the achievement of a ﬁne balance
between those that may be beneﬁcial (see the comments
on immune deviation above) and those that are dangerous.
The ﬁnal safety issue relates to the induction de novo of
an autoimmune process, for example, when an ASI study
uses a -cell autoantigen that is expressed in other tissues
as in the case of GAD65, which is expressed in the
peripheral and central nervous systems. To date, the
nonclinical and clinical experiences suggest that such a
complication remains only a theoretical risk; notably there
was no induction of neurological disease despite adminis-
tration of GAD65 with adjuvant in a regime that boosted
GAD-speciﬁc autoantibody titers to levels more typically
seen in patients with stiff-man syndrome (15).
Synthesizing these comments, there are theoretical risks
of ASI and for some of these risks, there are nonclinical
studies to indicate that theory can become reality; but this
is the exception rather than the rule, and clinical studies
have proved extremely safe.
Optimizing antigen-speciﬁc immunotherapy for the
clinic. Based on preclinical models, several factors are
emerging as critical in determining the outcome of anti-
gen-speciﬁc immunizations, most notably dose, route, ad-
juvant, and frequency of administration. Studies have
shown that too frequent antigen administrations, as well
as very high dosages, do not result in optimal induction of
immune regulation and tolerance. In addition, there is no
evidence that there is such a thing as “regulatory memory,”
and in most prevention studies so far, repeated adminis-
tration of the antigen has been required. Exceptions arise,
for example when certain adjuvants such as alum or
incomplete Freund’s adjuvant are used. Here, at least in
TABLE 2
Explanations for the paucity of antigen-speciﬁc immunotherapy studies in the intervention setting
“Biologics” and other
nonantigen-speciﬁc approaches Antigen-speciﬁc immunotherapy
Biomarkers Facile (e.g., reduction in B-cells during
anti-CD20 therapy)
Emerging but remain typically site and study-speciﬁc;
lack of consensus
Dosing and route of
administration
Clear treatment pathways from Phase
I studies and/or other diseases
Often difﬁcult and complex in ASI; issues over use of
adjuvants unresolved; optimal routes remain to be
determined
Preclinical models Generally robust and informative Translation not always straightforward (e.g., is the
intranasal route appropriate in humans; antigen or
peptide choice; timing of therapy in relation to
natural history)
Success in other autoimmune
diseases
Yes Not yet (but whole allergen and allergen peptide
immunotherapy are effective)
Target population All patients with type 1 diabetes Inclusion criteria may require staging to presence of
selected autoantibodies and their titre, and to HLA
type for peptides
Efﬁcacy Often effective as interventions Intervention is a tough arena for trials with
metabolic outcomes (i.e., C-peptide preservation)
Safety Variable but generally predictable Good
Biotechnology/Pharmaceutical
involvement
High Variable; e.g., there is still no Good Manufacturing
Practice (GMP) grade proinsulin; new Intellectual
Property (IP) relies upon novel modes of delivery
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adjuvant is sufﬁcient to prevent diabetes. In these cases,
rather than augmentation of nTregs or de novo induction
of iTregs or aTregs, an immune deviation to TH2 and
induction of TH2 memory cells that produce IL-5, -4,
and -13 might have occurred. This in itself might be very
beneﬁcial and the desired outcome of antigen-speciﬁc
immunization in type 1 diabetes. We might not need to
induce bona ﬁde Tregs after all (i.e., the FoxP3
CD127
low
CD25
high type), but a mere TH2 deviation could be
sufﬁcient. IL-4 is exquisitely protective in various animal
models for type 1 diabetes and has a large therapeutic
range, especially when delivered locally to the pancreatic
islets or lymph nodes via -cell antigen–speciﬁc Tregs
(30). Thus, choosing the correct adjuvant (i.e., a TH2-
deviating compound) might be the key to antigenic immu-
nization and long-term tolerance in type 1 diabetes (15).
Tolerance-inducing adjuvants are not an area of large-
scale research and are probably not in the development
pipelines of many pharmaceutical companies.
In addition, several other factors need to be resolved.
The most pressing issue is the precise dosing regimen.
From the studies in various animal models, it is known
that too high dosages might not be effective by leading to
the deletion of Tregs rather than their augmentation. In
murine models, for example, only oral insulin dosages
between 0.2 and 2 mg are effective when given twice per
week by oral gavage (31). Higher and lower dosages have
no strong effect on preventing diabetes, therefore there is
a strong need to translate dose regimens used in these
animal models to humans as accurately as possible. This
has not been achieved to date, at least in part because
there is no fully validated formula. However, the currently
utilized 7.5-mg dose in the oral insulin study of Diabetes
TrialNet, which mirrors that used in the Diabetes Preven-
tion Trial (DPT)-1 (16), is most likely too low compara-
tively and, based on animal models, less frequent dosing
with a higher dose should greatly increase efﬁcacy. This
factor could also explain the lack of efﬁcacy in the Finnish
nasal insulin diabetes prevention trial (39).
New strategies and creative approaches will be required
to more rationally and rapidly translate from mouse stud-
ies to human trials, as we will discuss in the next section.
Emerging strategies for antigen-speciﬁc immuno-
therapy: implementation and bold steps. The future is
not all bleak: several new strategies are emerging that may
well achieve success in enhancing the delivery and po-
tency of ASI and when assembled together, the ASI
portfolio offers a number of appealing options (Fig. 3).
These options include strategies for the delivery of multi-
ple epitopes from multiple antigens to mirror the approach
that is proving successful in clinical allergy; the use of
steroid hormone adjuvants (glucocorticoids and vitamin
D) to modulate APCs presenting autoantigens both in vitro
for adoptive transfer (32,33) and in vivo to enhance
tolerance induction in the skin; new methods for the
delivery of antigens to the gut using Lactococcus lactis
gene modiﬁed to deliver islet autoantigens and cytokines;
using soluble T-cell receptors speciﬁc for islet peptides
(for details, see http://naimit.eu/); and antigens coupled to
inert cells. As discussed above, these approaches tend to
center on novel modes of antigen delivery, perhaps par-
tially as a means to generate funding interest or intellec-
tual property and thus to sustain the effort. Additional
strategies will also be useful if conducted in parallel;
notable among these strategies is the emerging interest in
analyzing immune responses, tolerance, and ASI through
investigation of disease models generated in silico (34).
Notwithstanding these fertile new areas, there is a sense
that the progress made in getting antigens into the clinic
has stalled and requires renewed invigoration. There is
nothing intrinsically ﬂawed about oral or nasal antigen
administration or antigen injection. They have simply not
been fully evaluated in a staged developmental program.
As discussed above, much remains to be understood about
dose, regimen, and route. We would advocate a return to
Direct Antigen-
specific 
Immunotherapy 
Indirect Antigen-
specific
Immunotherapy
(“Trojan Horse”)
•Intranasal (whole antigen or 
peptide) 
•Oral (whole antigen) 
•Intradermal, subcutaneous 
or intramuscular (whole  
antigen, peptide or DNA;  
with or without adjuvant or 
skin conditioning)
Parenteral using tolerogenic  
DCs, blood cells or inert  
particles as carriers 
(whole antigen or peptide) 
Parenteral antigen-specific 
Tregs (primed ex vivo;
expanded ex vivo from   
in vivo precursors; gene 
modified “designer” Tregs) 
Using gene modified probiotic 
delivery (whole antigen or   
peptide) 
FIG. 3. Approaches currently under evaluation for delivery of antigen-speciﬁc immunotherapy. DCs, dendritic cells.
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studies with the emphasis on mechanistic outcomes. A
second line approach will be the development of suitable
combinations of antigens with immune modulators that
have been speciﬁcally selected to foster Treg function and
expansion while reducing the effector cell load. Such an
initiative could be very beneﬁcial in overcoming some of
these issues and, most importantly, enabling antigen-
speciﬁc Treg induction to be effective later during the
disease process, for example in individuals at high risk of
developing type 1 diabetes or in recently diagnosed pa-
tients (35). Animal studies using a combination of anti-
CD3 and nasal proinsulin peptide strongly support this
concept (36).
As a ﬁnal comment, one advance that could facilitate
rapid advances in these key areas relates to trial design.
Perhaps, for example, the emphasis in relation to out-
comes should shift away from metabolic recovery toward
an intense focus on immunological biomarkers. This could
be done in the context of small optimization trials. These
trials, in turn, would be considerably better informed if
another knowledge gap—namely the natural history of
such immunological biomarkers in the 1- to 2-year period
after diagnosis—were adequately mapped through longi-
tudinal studies. Going forward, these efforts should enable
the type 1 diabetes community to make informed deci-
sions about the merits of ASI and hopefully realize its
potential for “negotiating” with the immune system (37).
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